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Abstract
Background: Detection of mutations by DNA sequencing can be facilitated by scanning methods to identify
amplicons which may have mutations. Current scanning methods used for the detection of germline sequence
variants are laborious as they require post-PCR manipulation. High resolution melting (HRM) is a cost-effective rapid
screening strategy, which readily detects heterozygous variants by melting curve analysis of PCR products. It is well
suited to screening genes such as BRCA1 and BRCA2 as germline pathogenic mutations in these genes are always
heterozygous.
Methods: Assays for the analysis of all coding regions and intron-exon boundaries of BRCA1 and BRCA2 were
designed, and optimised. A final set of 94 assays which ran under identical amplification conditions were chosen
for BRCA1 (36) and BRCA2 (58). Significant attention was placed on primer design to enable reproducible detection
of mutations within the amplicon while minimising unnecessary detection of polymorphisms. Deoxyinosine
residues were incorporated into primers that overlay intronic polymorphisms. Multiple 384 well plates were used to
facilitate high throughput.
Results: 169 BRCA1 and 239 BRCA2 known sequence variants were used to test the amplicons. We also performed
an extensive blinded validation of the protocol with 384 separate patient DNAs. All heterozygous variants were
detected with the optimised assays.
Conclusions: This is the first HRM approach to screen the entire coding region of the BRCA1 and BRCA2 genes
using one set of reaction conditions in a multi plate 384 well format using specifically designed primers. The
parallel screening of a relatively large number of samples enables better detection of sequence variants. HRM has
the advantages of decreasing the necessary sequencing by more than 90%. This markedly reduced cost of
sequencing will result in BRCA1 and BRCA2 mutation testing becoming accessible to individuals who currently do
not undergo mutation testing because of the significant costs involved.
Background
Inactivating germline mutations in the BRCA1 and
BRCA2 tumour suppressor genes dramatically escalates
the risk of developing breast and/or ovarian cancer by
up to 20 fold [1-4]. Due to the highly penetrant nature
of germline mutations within BRCA1 and BRCA2, it is
of importance to identify a woman as being a carrier of
a mutation as early intervention measures including
breast screening and prophylactic bilateral salphingo-
oophorectomy or mastectomy can be offered [5]. More
recently, it has been recognised that BRCA1 or BRCA2
mutant tumours are sensitive to PARP inhibitors and
thus rapid and inexpensive BRCA1 and BRCA2 testing
may be of direct clinical utility [6].
BRCA1 and BRCA2 are very large genes. BRCA1 has 24
exons (22 of which are protein coding) that code for a
1863 amino acid protein while BRCA2 has 27 exons (26
coding) that code for a 3418 amino acid protein. Cur-
rently, Sanger sequencing is considered as the gold stan-
dard for identification of sequence variants within
BRCA1 and BRCA2. However, scanning methods have
been often employed in order to reduce costs and
improve turn around time. The major disadvantage of
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most scanning methods is that they require post-PCR
product manipulation which, in addition to the increased
workload, also carries the potential risks of sample misi-
dentification and contamination [7,8].
High Resolution Melting (HRM) is a post-PCR method
which enables the detection of sequence variations within
an amplified region of DNA. Using saturating concentra-
tions of a fluorescent dye which specifically intercalates
with double stranded DNA, the denaturation behavior of
an amplified region of DNA can be analysed. The dye
dissociates from the double stranded DNA as it dena-
tures into single stranded DNA and thus the melting can
be monitored using the decrease in fluorescence. Hetero-
zygous sequence variations are readily detected due to
the formation of heteroduplexes between variant and
wildtype strands that then have a characteristic early
melting profile [9,10].
HRM has the major advantage over other pre-sequen-
cing scanning methods in that it is performed in a “closed
tube” system. This eliminates the risk of post-PCR pro-
duct contamination during scanning while also reducing
processing time (especially when the PCR and HRM are
performed within the one instrument as in this study),
resulting in improved turn around times. HRM has effec-
tively replaced the previously most commonly used scan-
ning method, denaturing high pressure liquid
chromatography (DHPLC). It has better sensitivity and
specificity for the detection of variants than DHPLC
[7,8,11].
In this communication, we report the development of
an HRM-based assay system for mutation detection
within BRCA1 and BRCA2 using a 384 well plate format
both to facilitate the detection of mutations and to enable
high throughput scanning. As it is difficult to distinguish
heterozygosity for SNPs from heterozygosity of other
sequence variants, we have employed strategies for SNP
minimisation within amplicons. We also introduced the
use of deoxyinosine residues in HRM primers to enable
the siting of primers over clinically insignificant intronic
SNPs. The assay system is a robust BRCA1 and BRCA2
mutation scanning protocol that has had the most exten-
sive validation so far reported.
Results
Amplicon design principles
Amplicons were selected in order to analyse the entire
coding sequence and the intron-exon boundaries of
BRCA1 and BRCA2. Typically, one amplicon was
designed per exon. However, for longer exons or exons
with more complex melting domains, two or more over-
lapping amplicons were chosen.
Extensive in silico analysis was performed in order to
identify amplicons that would be suitable for both PCR
and HRM. The DNA melting prediction software
‘Poland’ [12] was used to choose amplicons which pre-
ferably had a single melting domain. In some cases,
amplicons with multiple domains were selected to keep
the overall number of amplicons low. This was espe-
cially the case where the amplicon was short. Where
double melting domains were unavoidable e.g. BRCA2
exon 11Q, the tested mutations were readily detectable
(Additional file 1 Figure S1).
In germline DNA, all pathogenic BRCA1 and BRCA2
mutations will exist in heterozygous form giving rise to
heteroduplexes that enhance variant detection by HRM.
Previous HRM studies have reported 100% sensitivity for
detection of heterozygous sequence variations in PCR
products up to 435 bp [13-15]. All of the amplicons in
this study were less than 405 bp. Although the homozy-
gous genotypes for some of the polymorphisms were
readily distinguishable e.g. the c.2612C>T in BRCA1
exon 11H (Additional file 2 Figure S2), others were not.
This was not considered a problem as our aim was to
identify heterozygous changes rather than to genotype
existing high frequency polymorphisms.
Primer design principles
In order for all of the assays to perform under the same
PCR and HRM conditions, primers were designed to have
an annealing temperature of 64-67°C using OligoCalc [16].
Primers were designed to minimise primer-dimer interfer-
ence and were screened to ensure specificity to the target
site using Amplify v3.1 [17]. Attention was paid to the 3’
ends of the primers ensuring that they were neither too
GC rich or AT rich.
Intronic polymorphisms within an amplicon decrease
the specificity of HRM assays for mutation detection as
they produce heterozygous melting profiles and thus
require sequencing to distinguish them from true muta-
tions. Primers were placed as close to exon boundaries as
possible while still leaving at least 5 intronic bases to
identify the most likely splicing mutations. This also
assisted in keeping the amplicon size lower. However,
where there were known or suspected pathogenic intro-
nic variants close to the exons listed in the Breast Cancer
Information Core Database (i.e. BRCA1 c.213-11T>G,
BRCA1 c.5194-12G>A and BRCA2 c.426-12_8del5), the
primers were moved further into the intron to enable the
detection of these variants [18].
A critical consideration in primer design for mutation
screening is that primers should not be placed over known
polymorphisms, even if they are comparatively rare. This
may lead to non-amplification of the polymorphic allele
and coexisting pathogenic mutation if in a cis relationship
with the polymorphism or false homozygosity of the inac-
tivating mutation if it exists in a trans relationship with
the polymorphic allele [19,20]. Care was thus taken to
identify known single nucleotide polymorphisms (SNPs)
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using the Basic Local Alignment Search Tool (BLAST)
[21]. Care was also taken to ensure that the primer sets
did not non-specifically amplify the BRCA1 partial pseu-
dogene where the homology extends into BRCA1 exon 2
[22].
When common or rare polymorphisms were present
in an intronic region that was otherwise optimal for pri-
mer placement, we incorporated a deoxyinosine residue
(dI) at the position of the polymorphism. Incorporating
a dI into the primer at the site of the polymorphism
allows equal amplification of both the wildtype and the
variant allele [23]. During amplification, complementary
bases will be inserted randomly producing a product
that is indistinguishable from wildtype by HRM as dI
will not form heteroduplexes regardless of which base it
is paired with. Consistent with this, we found that incor-
porating a dI into the primer at the location of the poly-
morphism was a good strategy for eliminating the
detection of the polymorphism while giving clean HRM
profiles suitable for both mutation detection and down-
stream sequencing of mutations. Polymorphisms that
were replaced by dI were, BRCA2 c.-26G>A (rs1799943)
which flanks the coding region of exon 2, BRCA2
c.7806-14T>C (rs9534262) and BRCA1 c.80+13A>G.
Amplification of both alleles of the polymorphism allows
the detection of all coexisting mutations while masking
the SNP. Figure 1 shows the example of detection of
both the BRCA2 c.26delC mutant allele and the wild
type allele where a dI in the primer has been used to
mask the c.-26 G>A polymorphism.
Protocol design
In HRM analysis, multiple samples for each amplicon
should be screened at the same time in order to enable
the ready detection of mutant sequences relative to mul-
tiple wild-type sequences as more samples act to
dampen stochastic variation. As most samples are wild-
type for any given amplicon, multiple samples will make
it easy to distinguish a mutation from the wildtype var-
iation. The use of 384 well plates facilitates the use of
multiple samples. We chose a batch size of either 10 (6
plates) or 22 samples (12 plates). A known wild type
control that was homozygous for all the common SNPs
and a no-template control were also included. The
amplicons were clustered into discrete areas on the
plate to minimise the temperature variation for each
amplicon (Additional file 3 Table S1 shows the layout).
Each primer set was initially tested using the standard
mastermix and PCR and HRM program, after which pri-
mer sets requiring additional optimisation were tested
using the simplified primer matrix. Only primer sets
which produced specific products as assessed on an
agarose gel and which both amplified efficiently and
melted in an acceptable profile were used for mutation
testing. Otherwise, new primer sets were designed for
the region. In addition, primers needed to give good
melt curves without any non-specific products.
The analysis was performed on a combined PCR and
HRM instrument allowing us to analyze HRM data in the
context of the PCR amplification information. During
analysis of the amplification for each amplicon, any out-
lying late amplifying replicates that were often associated
with false positive alterations in melting profile were
removed from the analysis.
Optimizing the set of HRM amplicons against a panel of
known sequence variants
In the final protocol, 36 amplicons were used to analyze
BRCA1 while 58 amplicons were used to analyze BRCA2
(Additional file 4 Table S2). Initially, a provisional set of
assays were designed. For these, a large panel of muta-
tion positive and other sequence variant controls were
Figure 1 Detection of both BRCA2 c.26delC mutant and wild type alleles where deoxyinosine is used at the c.-26G>A SNP. The red and
blue samples both contain the c.26delC deletion but differ according to their genotype for the BRCA2 c.-26G>A polymorphism. The red profile is
homozygous wildtype for the polymorphism. The blue profile is heterozygous for the polymorphism. The left panel shows the difference curves
where the baseline comprises both wildtype (grey) and heterozygous (green) genotypes. The right panel shows the corresponding melting peak
curves. The difference curves are independent of the SNP meaning that both alleles are equally amplified using the deoxyinosine containing
primers
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used to test the ability of the amplicons to identify
sequence variants. The controls were analysed alongside
multiple wild type controls derived from women that
had previously tested negative for sequence variants.
Some amplicons required further optimisation of the
primer concentration which was determined using a
range of concentrations of the forward and reverse pri-
mers in a primer matrix [24]. Agarose gels were run for
each primer set to ensure that the correct size product
was produced and that there were no non-specific pro-
ducts or primer dimers formed.
Mutation detection was carried out using all the three
visualisations of the raw data (normalised and tempera-
ture shifted melting curves, normalised and temperature
shifted difference curves, and the negative first derivative
curves which give a melting peak curve). Melting peak
curves are independent of normalisation and tempera-
ture shifting. However in general, the difference curve
view was the most useful. Normalising the data at the
pre-and post-melt phases of HRM allows samples to be
directly compared.
Surprisingly since all heterozygous mutations might be
expected to have pronounced heteroduplexes, some
mutations, especially single base insertions and dele-
tions, gave rise to more subtle shifts. Previous commu-
nications have also noted the difficulty in detecting
single base insertion or deletion mutations [25,26]. We
have found this to be most marked when the single base
insertion or deletion exists within extended runs of a
single nucleotide. Such variations create little Tm differ-
ence and are consequently more subtle with HRM.
While we did experiment with additives such as DMSO
with some success for difficult amplicons, we finally
focused on amplicon design to maintain consistency in
mastermix set-up.
Figure 2 shows an example where the c.2885delA
mutation in BRCA1 is less apparent than the other
sequence variants, particularly when the melting peak
curves are examined. Nevertheless the mutation is still
obviously different from the wildtype. While single
nucleotide changes and multiple base insertions and
deletions are usually best detected using the normalised
and temperature shifted melting curves, single base
insertions and deletions are better detected on a differ-
ence curve relative to a wildtype control.
In some amplicons, certain mutations were initially not
detected by the HRM assays. The exons that proved most
problematic were BRCA1 exon 7 and BRCA2 exons 3, 11
and 15. For example, in BRCA1 exon 7, both the single
base insertion c.329insA and single base deletion muta-
tion c.302-2delA were not detected with the original
amplicon. As a result, new amplicons were designed,
optimised and validated in order to also detect the muta-
tions and checked against the other mutation controls.
For BRCA2 amplicon 11I, we were not initially able to
detect the c.4512insT which inserted an extra T into a
run of 6 Ts and thus included an extra amplicon (11Is)
that covered a shorter region and was able to resolve this
mutation (data not shown).
Another solution was to divide problematic amplicons
into 2 overlapping shorter amplicons making the melting
profile within each amplicon less complex based on
Poland analysis (Figure 3). By decreasing the size of the
amplicon, we could detect all available mutations, includ-
ing those that are located within repeat regions (Figure 4).
A large number of positive controls were tested for
BRCA1 (184) and BRCA2 (256) (Additional file 5 Table
S3). While most amplicons had multiple mutation con-
trols (mean = 4.25), a few amplicons did not possess
any mutation controls. These amplicons were BRCA1
Figure 2 Detection of different mutations within the same amplicon (BRCA1 11I region). The left panel shows the difference curves and
the right panel shows the corresponding melting peak curves. All mutations produce obvious biphasic melting which is caused by the earlier
melting of the heteroduplexes. The normalised and temperature-shifted difference plots in the left panel allow easy detection of the
c.2863delTCATC (navy), c.2800C>T (red) and c.2885delA (green) relative to the wildtype HRM profile (grey). The melting peak curves in the right
panel show that the c.2885delA is the most subtle mutation in that there is a minimal early melting heteroduplex component compared to the
c.2863delTCATC and c.2800C>T mutations.
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exons 9 and 22, BRCA2 exons 11J2, exon 12, exon 26
and exon 27A. However, during subsequent blinded
testing, mutations in all of these exons except 27A were
detected. These and other new variants that were
detected are detailed in Additional file 6 Table S4.
Validation of the assays
In addition to the testing of the individual amplicons,
two sets of validations using full HRM screens were
performed. In these validations, we undertook a deliber-
ate strategy of sequencing all reactions with minor
deviations from wildtype i.e. those that were likely to be
“false positives”. As discussed, some pathogenic muta-
tions can produce subtle changes to the melting beha-
viour. All reactions which were suspicious including
those that had one aberrant replicate were sequenced.
Thus, likely false positives were targeted for sequencing
as the consequences of inadvertently missing a mutation
Figure 3 The influence of amplicon choice on mutation detection. The top panels show difference curves and melting peak curves for the
original BRCA1 exon 7 amplicon which did not readily detect single base insertions or deletions. While the c.427G>T (red) and the c.314A>G
(green) mutations are readily detectable in both visualisations, the pathogenic c.329insA (navy) and c.302-2delA (yellow) single base pair insertion
and deletion mutations were difficult to detect as they melt like the wildtype controls (grey). The original amplicon was then divided into two
overlapping amplicons. The bottom panels show difference curves and melting peak curves for BRCA1 amplicon exon 7A which detects the
single base insertion and deletion. The c.329insA (navy) and c.302-2delA (yellow) clearly differ from the wildtype controls (grey) in the shorter
amplicon. The BRCA1 c.314A>G (dark green) mutation is also readily detectable in both visualisations.
Figure 4 Detection of an insertion within a long nucleotide repeat by HRM (BRCA2 exon 23). The mutation c.9097insA (green) is an
insertion of an adenine nucleotide into an 8 adenine repeat. Like the other mutations here; c.9117G>A (red) and c.9117+1G>A (navy); it is
readily distinguishable from the wildtype (grey) in this 264 bp amplicon.
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are more serious than calling a false positive. We also
sequenced all those variants that were likely to be SNPs.
In the first set, 266 samples which were sent for diag-
nostic testing by bidirectional Sanger sequencing were
concurrently screened by the first version of our full
HRM screen. The operator was blinded to the results of
the mutation sequencing until the samples had been
scored as to whether they contained variants by HRM.
Subsequently the results of HRM and sequencing were
compared. All variants including heterozygous SNPs
were considered in the analysis.
22,797 amplicons were analysed and 7.5% were identi-
fied as requiring sequencing to identify the variant while
92.5% were considered to be wildtype. All 35 pathogenic
mutations (13% of DNA samples) identified by sequen-
cing were also detected by the HRM screening. The cal-
culated sensitivity for the detection of heterozygous
variants (including SNPs) was 99.8% (1595/1599) while
the specificity was 99.4% (21,070/21,192). The positive
predictive value was 92.9% while the negative predictive
value was 99.98%. At this stage, the BRCA1 c.5074
+3A>C, BRCA2 c.1834G>A, c.2971A>G, c.3807T>C and
c.9458G>C variants were not detectable but subsequent
amplicon redesign as used in the final protocol led to
their detection and an effective sensitivity of 100%.
A second validation was performed by retrospectively
re-screening 118 archival samples which were previously
reported as negative for germline inactivating mutations
within BRCA1 and BRCA2 with the final version of the
protocol. These samples had previously undergone test-
ing using a combination of testing procedures including
protein truncation testing (PTT) and partial Sanger
sequencing. Some of these samples had only been tested
for one of the genes or had just undergone PTT testing
for mutations in large exons. In the second validation,
11,092 fragments were analysed and 92.7% of amplicons
were called wildtype. 7.3% of amplicons contained var-
iants that required further investigation by sequencing.
Sensitivity was 100% while specificity was 99.75%. The
positive predictive value was 98.98% while the negative
predictive value was 100%. The positive predictive value
was decreased due to the deliberate strategy of also
choosing reactions with minor deviations from wildtype
that were likely to be “false positives” by HRM.
Once again, the positive predictive value was
decreased due to the detection of “false positives” by
HRM that were identified as wildtype by sequencing.
Eighteen amplicons were “falsely positive” by HRM.
Importantly, no amplicons were falsely negative by
HRM.
Mutations co-existing with polymorphisms
In some cases, mutations may be present close to a
common or rare polymorphism. De Juan et al. (2009)
raised the theoretical concerns that pathogenic muta-
tions which coexist with polymorphisms may distort the
HRM curve and make it appear like a normal sequence
[27]. We consider this extremely unlikely as greater
instability (early melting) would be caused by multiple
populations of heteroduplexes formed as a result of the
two sequence variants. In support of this, we found sev-
eral examples of a mutation coexisting with a common
polymorphism and resulting in a greater difference
between the melting curves of the doubly variant poly-
morphic sample and the wildtype (Figure 5).
Detection of mutations adjacent to the 3’ end of the
primers
It has been argued by some authors that mutations close
to the primers are more difficult to detect than more
centrally placed mutations. While it has been reported
that the ability to detect mutations decreases as the
Figure 5 Two variations within the same sample result in greater HRM differences. (BRCA1 exon 13). The left panel shows the difference
plot where 3 samples have been compared to the wildtype controls (grey). The green profile represents the a heterozygote for common
polymorphism c.4308T>C while the blue represents the mutation c.4327C>T. The presence of both sequence variants (red) results in greater
instability than each individual sequence variation due to the double mismatch in heteroduplexes. The right panel with melting peak curves
show the complex melting nature of two co-existing sequence variants (red).
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distance between the primer and the mutation decreases
[8,28], we were able to detect mutations immediately
adjacent to the 3’ end of the primer; an example being
the BRCA2 c.1365A>G polymorphism in amplicon exon
10C (Figure 6). Other publications have confirmed that
the location of the sequence variation within the ampli-
con does not affect the ability of HRM to detect the var-
iation [9,29]. Van der Stoep et al. (2009) also reported
detecting mutations up to 2 bp from the end of the pri-
mer [25].
Discussion
Current dideoxy (Sanger) sequencing based methods for
mutation identification are expensive and labor intensive
even with a high degree of automation. Scanning meth-
odologies can markedly reduce the amount of sequen-
cing by identifying the limited number of PCR
amplicons carrying variant sequences. High resolution
melting has become the method of choice for scanning
as it can be performed immediately after PCR amplifica-
tion in a seamless closed tube protocol on a single
instrument. It is also preferable to other scanning meth-
ods as it does not involve out-of-tube manipulation of
the PCR product thereby reducing the potential for PCR
contamination. Well designed and validated HRM assays
detect practically every sequence variant [30].
Our aim was to develop a high throughput HRM pro-
tocol in order to enable BRCA1 and BRCA2 testing to
be performed at considerably lower cost without com-
promising sensitivity or specificity. The cost reduction is
significant as the number of amplicons to be sequenced
is reduced by more than 90%. This involved sequencing
of all variants. The majority of these turned out to be
SNPs as expected. Within a research setting, costs could
be further reduced by not sequencing those samples
from amplicons spanning a common SNP where the
melting curves were identical to those of the SNP.
An extensive validation process confirmed that HRM is
a highly effective screen for the detection of heterozygous
sequence variants within the BRCA1 and BRCA2 genes.
Since pathogenic germline mutations always exist in a
heterozygous state within germline DNA and homozy-
gous germline variants only exist for non-clinically
important variants such as polymorphisms, HRM is thus
ideal for minimizing the burden of sequencing.
In the past, a combined pre-sequencing screening pro-
tocol of PTT and DHPLC followed by sequencing of
amplicons found to possess sequence variants was often
used. DHPLC was formerly the gold standard for variant
scanning [31]. Comparative studies have shown that
HRM has superior sensitivity and specificity than
DHPLC [7,8]. Whereas HRM is able to detect all hetero-
zygous mutations and some homozygous mutations
within amplicons with complex melting domains,
DHPLC sensitivity and specificity can be challenged
within multiple melting domains. DHPLC also requires
that the column temperature must also be empirically
optimised for each amplicon whereas; we have devel-
oped HRM so that all amplicons undergo the same PCR
and HRM reaction conditions. Thus, multiple HRM
analyses can thus be carried out in parallel contrasting
with DHPLC in which analyses are sequential.
HRM has been used as a rapid screen for BRCA1 and
BRCA2 founder mutations. Dufresne et al (2006) first
reported HRM for the detection of the 3 common Ash-
kenazi founder mutations using short amplicons [32].
We subsequently established that long amplicons could
be successfully used for the Ashkenazi mutations [33].
This enabled the detection of other mutations, and this
principle underlies the experimental design in this paper
where it is often necessary to screen comparatively long
stretches of DNA in order to efficiently scan the full
coding sequence of the genes. Other populations studied
for founder mutations by HRM include Spaniards,
Greeks and Southern Chinese [27,34,35].
Full screening by HRM of exons including intron-exon
boundaries has been reported for BRCA1 [25], and for
BRCA1 and BRCA2 [26,36]. We have independently
Figure 6 Detection of a sequence variation immediately adjacent to the 3’ end of a primer. The class 1 SNP (BRCA2 c.1365A>G) (red) is
readily detectable at the position immediately adjacent (1 base pair) to the 3’ end of the reverse primer in this 232 bp amplicon (BRCA2 exon 10C).
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developed a comprehensive HRM protocol for full
screening of exons and intron-exon boundaries for both
genes. We aimed to design all the PCR assays so they
could be amplified under identical conditions using a
minimal amount of DNA in a high throughput (384
well) approach. Previous communications used 96 well
plates and the layout and ergonomics were not
described [26,36].
Each assay was tested using as many positive mutation
controls as available to us. Where sequence variations were
not immediately detectable as occurred in a few cases, new
primers were optimised for the detection of that variation
in addition to the other positive controls present within the
amplicons. Extensive testing of the amplicons with known
mutations and redesign where there were detection diffi-
culties, resulted in a set of primers that enabled the detec-
tion of 100% of mutations in the panel.
Two sets of blinded validation experiments were per-
formed, making this the most extensively validated HRM
protocol described. Firstly, validation was performed by a
prospective blinded screening of 266 samples sent in for
diagnostic mutation testing using Sanger sequencing. An
additional retrospective blinded validation was performed
by screening 118 previously tested samples in which no
mutations had been detected at the time of either full or
partial testing. All previously described sequence variants
could be detected and a pathogenic mutation in a pre-
viously untested region was detected.
HRM screening is most cost-effective in the absence
of a large number of SNPs. The relatively low amount
of SNPs in BRCA1 and BRCA2 make HRM a suitable
mutation scanning technique for these genes. We used
appropriate primer design (including the use of inosines)
and placement to further minimise the SNPs within
amplicons. Nevertheless those SNPs that occur within
coding sequences could not be eliminated. While
sequencing burden is significantly reduced via pre-
sequencing HRM screening, approximately 7% of ampli-
cons still require sequencing which is largely due to the
detection of clinically non-significant polymorphisms. In
our confirmatory sequencing, 97% of the identified
sequences were SNPs, entailing an average of 7 ampli-
cons that needed to be screened per patient.
Others have incorporated SNP genotyping using unla-
belled probes as part of their protocol [37,38]. Although
we have shown earlier that samples that are heterozy-
gous for both a polymorphism and a mutation can be
distinguished from those carrying a polymorphism
alone, we believe that it is safer to sequence all sequence
variants in a diagnostic scenario.
Conclusions
Our protocol comprises 94 PCR amplicons that cover
the complete coding region along with intron-exon
boundaries of BRCA1 and BRCA2. The amplicons are
designed to be run under the same PCR and HRM con-
ditions. A 384 well format allows the greatest number of
HRM assays to be performed at the one time as well as
allowing more reliable detection of mutations. The
closed-tube format used here has clear advantages over
other screening technologies which require post-PCR
product manipulation as there is a complete elimination
of all risk of PCR product contamination along with
considerable reduction in manual handling [8,39,40]. It
was shown that the incorporation of deoxyinosine into
the primers was useful in both allowing flexible primer
placement and reducing the amount of subsequent
sequencing necessary.
The protocol has applications within all diagnostic and
research projects that have budget limitations. It can be
run at a fraction of the cost of a full sequencing
approach as the sequencing burden is relieved by more
than 90%. This marked reduction in cost will enable
BRCA1 and BRCA2 mutation detection to be more
widely used especially for those who have a positive
family history for breast or ovarian cancer but who do
not meet current algorithms for mutation testing. The
assay design principles in this paper are also relevant to
the HRM screening of other germline mutations.
Methods
Patient DNA Samples
Samples and control DNA for the HRM optimisation
and targeted mutation detection were obtained from the
Diagnostic Molecular Pathology laboratory at the Peter
MacCallum Cancer Centre and from the Kathleen Cun-
ningham Foundation Consortium for Research into
Familial Breast Cancer (kConFab). Samples for the
blinded prospective validation (266) and for the blinded
retrospective validation (118) were obtained from the
Diagnostic Molecular Pathology laboratory at the Peter
MacCallum Cancer Centre. Additional blinded BRCA2
mutation controls (18) and blinded DNA samples (10)
were obtained from the Hunter Area Pathology Service,
John Hunter Hospital and Royal Melbourne Hospital,
respectively. This study was conducted under guidelines
approved by the Peter MacCallum Ethics of Human
Research Committee (approval number 03/90). All indi-
viduals had previously consented for germline BRCA1
and BRCA2 testing.
Setting up of reactions
EpMotion 5075 (Eppendorf AG, Eppendorf, Germany)
programs were designed for the dispensing of the mas-
termix and samples into pre-designated wells of a 384
well thermoplate (Roche Diagnostics, Penzberg, Ger-
many). All reactions were set up in duplicate. Two alter-
native programs were used; a 6 plate program with 16
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assays per plate screening 10 samples plus 1 wildtype
control and 1 no-template control and a 12 plate pro-
gram with 8 assays per plate screening 22 samples plus
1 wildtype control and a no-template control. The plate
layouts are set out in Additional file 3 Table S1.
Following preparation of the mastermix, 7 uL was ali-
quotted into each pre-designated well. As multi-dispen-
sing on the EpMotion is restricted to volumes equal or
greater than 3 uL, the DNA (10 ng per reaction) was
adjusted with PCR grade H2O to 3.3 ng/μl. The total
time taken to set up each plate was less than 1 hour as
mastermix dispensation and DNA addition each
required 20 minutes.
PCR and HRM conditions
Samples were run in duplicate using 10 ng of genomic
DNA, 250 nM of forward and reverse primers, master-
mix and PCR grade water in a total reaction volume of
10 uL. Either LightScanner Master Mix (Idaho Technol-
ogy, Salt Lake City, UT) or TrendBio Master Mix (Tren-
dBio Pty Ltd, Melbourne, Australia), supplemented by
LCGreenPlus™ Hi-Res Melting Dye (Idaho Technology)
were used. The primers for BRCA1 exons 11I, 11M, 17
and 18, and BRCA2 exon 16 were used at 500 nM final
concentration. The primer sequences used are listed in
Additional file 4 Table S2.
PCR and HRM was performed on the LightCycler 480
(Roche Diagnostics). Template amplification conditions
included an activation step of 10 minutes at 95°C fol-
lowed by 45 denaturation cycles of 95°C for 10 seconds,
annealing for 10 seconds comprising 10 cycles of a
touchdown from 65 to 55°C at 1°C/cycle followed by 35
cycles at 55°C, and extension at 72°C for 30 seconds.
Prior to the HRM, a heteroduplex forming step involved
heating the PCR products to 95°C for 1 minute and a
rapid cooling to 45°C for 1 minute. HRM was per-
formed from 72°C through to 95°C at a temperature
gradient of 1°C per second, acquiring 30 data points
per °C.
HRM analysis
The melting curves were normalised at the pre-melt
(100% fluorescence) and post-melt (0% fluorescence)
stages using the supplied software temperature shifting
[13] was used to compensate for temperature variation
between wells and enabled samples with similar dena-
turation behaviour to be grouped. While there may be
some loss of information with increasing temperature
shifts, in particular, loss of detection of homozygous var-
iations, visualisation of heterozygous profiles, particu-
larly those of single base insertions and deletions is
enhanced at greater temperature shifts. The default
threshold used in our study was 5. However, the
threshold can be lowered when an ambiguous sample is
being examined. We used a default sensitivity setting of
0.70.
Samples with aberrant melting behavior were chosen
as discussed in the Results section. A conservative
approach was taken which maximises sensitivity at the
loss of specificity i.e. some false positive calls were
sequenced to avoid missing some of the more subtle
mutations.
Sequencing
Chosen samples were directly sequenced from a 1/35
dilution of the HRM product using the BigDye Termi-
nator v3.1 cycle sequencing kit (Applied Biosystems,
Foster City, CA). Following manual ethanol precipitation
and clean up, Hi-Di™ Formamide (Applied Biosystems)
denaturation, the samples were analysed on the ABI
3730 DNA sequencer (Applied Biosystems). The result-
ing sequence data was analyzed with Sequencher soft-
ware, version 4.9 (Gene Codes, Ann Arbor, MI).
Additional material
Additional file 1: Figure S1: Detection of mutations within a double
melting domain. Despite the very clear double melting domain, both
mutations; BRCA2 c.6743del13bp (blue) and BRCA2 c.6821G>T (green) are
readily differentiated from the wildtype (grey) in this 221bp amplicon.
Additional file 2: Figure S2: Visualisation of all three genotypes of
the BRCA1 c.2612C>T SNP. The wildtype C/C homozygote is distinct
from the T/T homozygote. The heterozygote has a broader melting peak
which is due to the combined melting peaks of the homoduplex and
heteroduplex populations.
Additional file 3: Table S1: Reaction layout. This table shows the
layout used for each of the 12 plates in a 22 sample run. Each plate can
run 8 assays with 22 test samples, a wildtype control and a no template
control.
Additional file 4: Table S2: PCR primer sequences. This table shows
the final set of primers used. M13 sequences, where used, are indicated
in bold.
Additional file 5: Table S3: List of known variants used in testing.
These represent the known mutations that were tested for BRCA1 and
BRCA2.
Additional file 6: Table S4: List of previously untested variants
found during validation. These are the previously undetected variants
that were detected during blinded testing.
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